Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose 177Lu-PSMA versus 225Ac-PSMA in 177Lu-refractory mCRPC
ChiCTR2600131867Phase 2Not yet recruiting
- Sponsor
- Affiliated Hospital of Southwest Medical University
- Start
- Sep 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lutetium lu 177 vipivotide tetraxetan and BAY 3563254 in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Affiliated Hospital of Southwest Medical University. Primary endpoints: radiographic progression-free survival, PSA50 response rate and 1 more. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
lutetium lu 177 vipivotide tetraxetanBAY 3563254
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on ChiCTR2600131867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131867.